{"markup":"\u003C!DOCTYPE html PUBLIC \u0022-\/\/W3C\/\/DTD HTML 4.0 Transitional\/\/EN\u0022 \u0022http:\/\/www.w3.org\/TR\/REC-html40\/loose.dtd\u0022\u003E\n\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022 content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022 dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022 foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022 og=\u0022http:\/\/ogp.me\/ns#\u0022 rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022 sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022 sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022 skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022 xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022 mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\ngoogletag.slots[\u0022mpu\u0022] = googletag.defineSlot(\u0022\/21798771943\/JITC-MPU\u0022, [[300, 250], [300, 600], [300, 300], [600, 500]], \u0022dfp-ad-mpu\u0022)\n  .addService(googletag.pubads());\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/www.highwirestage.com\/sites\/default\/files\/js\/js_tC-Wb03AOcixlvV_-2WciA-geUEdV5eGfsQlr4DE1s4.js\u0022\u003E\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/d1bxh8uas1mnw7.cloudfront.net\/assets\/embed.js\u0022\u003E\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/www.highwirestage.com\/sites\/default\/files\/js\/js_U2pncm4Q4A7IJl4J_deoOoy8h9tU-3gxfOF4iwZdk_g.js\u0022\u003E\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/www.highwirestage.com\/sites\/default\/files\/js\/js_rvqD3pd7j-PZ6JZdAHt2fB3_x3qj-q5uJ__00yD2B_k.js\u0022\u003E\u003C\/script\u003E\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022panels_ajax_pane\u0022:{\u0022new-70fd4c70-563e-4b94-ae3b-2a97f3980c13\u0022:\u0022{\\u0022encrypted\\u0022:\\u0022{\\\\\\u0022encrypted\\\\\\u0022:\\\\\\u0022YeAT7wAgUtrw\\\\\\\\\\\\\\\/E2XLqpzW2dtLp4T9XBzqnY0iVpsl69muReZLkx2OSshw2yAajF0LerCU+f2DczgoDTtk6odYhPyODeyxaT08KWGnmXWeGisPXDuYGTAFNAqccI7OQHPhWrR9xqCNZ0egI2F+ysZlS6nIA1X+SntHuGjf5rGo93BHYa9ErX7y7D+E5Vesa8gujK9+hQZh70rNGi1dKevbD2JtZSyqscZTpfhio1Ov0jbOdq6eZlzACtW9hxwczQn8V6QHnjyI2oDmBYMr\\\\\\\\\\\\\\\/pKnkdIONqSmccHu1ikB19s+93JikLst3TbWWdELc+REhHklbjB1L\\\\\\\\\\\\\\\/e6a8mkOACo+eRU4azQDnNFkGTDJainj1UAXO6XU28qpkDMigW1MxWlTANRvciCe8g4mIePx0O0odaYDtzAYxABFCxZIOt1qErNiTwwfM+Y0gVRKN5uJnYzKuReGjkAxIY8fU\\\\\\\\\\\\\\\/SE4YUz8LtPJjZ0df1lalnbqxNwtIDXA0aPzpSWUV67UkAJlu0e\\\\\\\\\\\\\\\/mog4jhmfOPHpEbEwjQZDsRdrj5DTNAcdio3z2m+xHHaMkx8jioMDfQRNcUJ8pp0qMnFNa7gl8M2gr6oNmOKeWldoPoIPnvrFB2Y9T\\\\\\\\\\\\\\\/dwSVI0ZUdGagJPgaWnM3yWnKv3UYp3oJRuQeWA8WVTxzaRDD04RvZeulSkk6Sfhf4YR6t+aZSI6c+Tlv2wlkPbg0gsS6B5\\\\\\\\\\\\\\\/4SZa8jnF7VGhWxOdPVVTdy7mRRjzjXsjdERycLw2GoHzWCKh2iF0lWueLPnfnYbG+wKEe0VHA8Cw9f0uQgRrsveIWr0xsJrslVqBjddJ\\\\\\\\\\\\\\\/BPYIRlVpshsuLziXj\\\\\\\\\\\\\\\/78bJoRYO9+iHs2uTtLTHC2ynkBGiF3NjbeF4Ad\\\\\\\\\\\\\\\/FnaTD7MgGAio8jcxJ5VZN1BlGjuwl25aX5d7cEC+K2GeGMC+yd1qj+HjWVbm6EItKPGhyiT2cYeeODsJnOFnLbsax3AdoeVq9Amn86Lm0KDgIWfGS+VNwRQQG2pxA2cl1DcxrbVVfGvM+496Wg\\\\\\\\\\\\\\\/O9AYs9DqbHs9QvKT9kW530H4df6GMf4cMMVIfxTP3QpwMfvNH+383OaEpCq7ltt5nVts\\\\\\\\\\\\\\\/\\\\\\\\\\\\\\\/kIEVmoHpSjMqLRwacFFgcZfzhm0zz1uWL84\\\\\\\\\\\\\\\/a5+GbSZVFD+7IDkNoa2uyTpHMveWemNYVIe+xcTdB7Yx5svkA+Amuyfc07T0u75J4tBESCDk5HxMWhVc5ps8BPbdjL5fPo8p5J\\\\\\\\\\\\\\\/1\\\\\\\\\\\\\\\/+PgJR18\\\\\\\\\\\\\\\/IF7o7gyRcCZ0aSs6hoih04HjrM8dH36McTUTsDoR8+j4jft4RgFCwgms3CjxfhrXw5OHlJIj26+q1BcHDXKqE1HtnxurrRDW78siFD3XOjT5JECw+\\\\\\\\\\\\\\\/4dUtQzN0StLE1eJBHa06sEtYlWJPylmyl55kzqyzD0MQ+Ej1Lk0FjG3vEwQA84Bk2bh79z0WQfv3idhV6+vcxD8SVa6DfLzRwisHX3tlrDyAqCP8cyimgT5KsyD\\\\\\\\\\\\\\\/jq5qfP5VjO1m5rRfKpljhu+DOHzzI5kOPDq4v1BAi9yl6pMuY9wATU8TR+4WC9W0sbb1tohibXRUNrBN+FNlj9RAN1amJT1N7GlY3NVwai3uPT0iNtSTnqQmF8nsutGiEYUtLvUfHnsp5PNWdbqhOo23zk1ifZxuFg3FwYkO9ynMMlerkwxDCLpt7nTSzYKvz6Sb4q7oetKA11aBvbwcGUqL\\\\\\\\\\\\\\\/wLq59j1uMBCB5NBnc3VlvURWTDdvXIQX1c0I2y5jHNHBTt+FH9ZLN2UGo3yqNz97nJrQ8t4+pRGvc2ACwtqvFindpO\\\\\\\\\\\\\\\/CvEU9SPW\\\\\\\\\\\\\\\/SlLHveJR4w+l2sttsxD67fgP3KMpclYmK6CzldIFvFHp+pTwLCNvF6aLyuPhYOuNrF1bzK73LCfAYPaSLPgm+5lrunSOssvfGchMrYVLwTDRDi2J5+Bp4lNdqOloIBDp\\\\\\\\\\\\\\\/6RH6gZ\\\\\\\\\\\\\\\/30BsDgM3pd674gWdsJjcumbzZ1cL5Xbnkq\\\\\\\\\\\\\\\/ExZVEQEatsca2Lxv9ZD6u+9khroRW\\\\\\\\\\\\\\\/zn12IBPyEgfrJ7I4LIR\\\\\\\\\\\\\\\/A2u3XvMsH9GLwDBIFpYwNH+fOOdulW3Q7JZRFo7oSaEukjrsbuBXFfUmQROi0HQnfR4bUsme2kE3z8o27lFhyrHnh3kYRJE33HaDqzD\\\\\\\\\\\\\\\/NEr4mX5OzHCuPrkFmZe3ckb8cu2MHYMDcKVMyCeNO\\\\\\\\\\\\\\\/ZFXheLA5F5SY+k34sy2B1TSCrpmD3caPsPYH0M\\\\\\\\\\\\\\\/KKPMTT\\\\\\\\\\\\\\\/KHudgw7xpyNSE7h6W01ypvxcQst83AsjwRVeCRRcm9bY1\\\\\\\\\\\\\\\/xGEmWUPSJC7tvBEaDotJ3ZRT6cL+qTpNzdaWtoa9FrToFCsxXV7clKoqyY6Koe9hlRpAqaMBNsTl4Hwhq5uFCoIoqaMJZE0ysrNtkmwjTE\\\\\\\\\\\\\\\/qnBqknXJv0artPsh6h0Ubifl9a2\\\\\\\\\\\\\\\/yYRo5lbZMj8\\\\\\\\\\\\\\\/Qndz1w3Xyzz41Xa+6sjNhV3CZRJbfDCJVFezXVjzrfi8lDvSnvLFPBe2GGmTxWgqIy0Ozjb2+rk+Evg2FtDrfXfDb\\\\\\\\\\\\\\\/D4qtZtdL4H8kxz6YHbjf2+w1j1kOzLtvCeKVG+2v1eWdq0U\\\\\\\\\\\\\\\/eCewCUqMJSmY\\\\\\\\\\\\\\\/3CSRofBbfLS1VSEqHKQ7LJNddF+xHzivy+XyimcktxyvrJnn63Trvi6Zqyg=\\\\\\u0022,\\\\\\u0022iv\\\\\\u0022:\\\\\\u0022eC2ihfH9PGtMaQjGLFT61w==\\\\\\u0022,\\\\\\u0022salt\\\\\\u0022:\\\\\\u00223fcf69c0544933648ca27e63b3137e55\\\\\\u0022}\\u0022,\\u0022hmac\\u0022:\\u00221585ea647cdd52154dc2db48ef5f2fd2c07b3e492339f381637b675bc157bbe0\\u0022}\u0022},\u0022highwire\u0022:{\u0022ac\u0022:{\u0022\\\/jitc\\\/8\\\/1\\\/e000878.atom\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022\u0022,\u0022apath\u0022:\u0022\\\/jitc\\\/8\\\/1\\\/e000878.atom\u0022,\u0022jcode\u0022:\u0022jitc\u0022}},\u0022markup\u0022:[{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022jitc;8\\\/1\\\/e000878\u0022},{\u0022requested\u0022:\u0022abstract\u0022,\u0022variant\u0022:\u0022pdf-extract\u0022,\u0022view\u0022:null,\u0022pisa\u0022:\u0022jitc;8\\\/1\\\/e000878\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022jitc;8\\\/1\\\/e000878\u0022},{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022jitc;8\\\/1\\\/e000878\u0022}],\u0022processed\u0022:[\u0022highwire_math\u0022]},\u0022MutationObserver\u0022:{\u0022js\u0022:\u0022\\\/sites\\\/all\\\/libraries\\\/mutationobserver\\\/MutationObserver.js\u0022},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u00221\u0022:1,\u0022sites\\\/default\\\/modules\\\/jnl_template_bmjj\\\/plugins\\\/highwire_markup_process\\\/js\\\/bmjj_author_affiliates.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/js\\\/highwire.javascript.pdf_extract.js\u0022:1,\u0022https:\\\/\\\/d1bxh8uas1mnw7.cloudfront.net\\\/assets\\\/embed.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/content_types\\\/js\\\/highwire_altmetrics.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/panels_ajax_pane\\\/panels_ajax_pane.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/www.highwirestage.com\/sites\/default\/files\/advagg_css\/css__WQiS3ck4zk_oYJMdLhTT-CHpv_wd1TntgyolXxchYqw__H8IDiO0U5hxt6_zxX1yD5dKF2jP5qm4oe8UqdAAcLMU__3qvfz4I9k5oUIeimOjbmdyh6ZgM-xweyVc5gub1_nR4.css\u0022 media=\u0022all\u0022\u003E\u003Clink rel=\u0022stylesheet\u0022 type=\u0022text\/css\u0022 href=\u0022\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0022\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-jnl-template-bmjj-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022\u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup author-affiliates col-narrow-12 author-affiliates-corresp article\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 class=\u0022content-block-markup\u0022 xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 class=\u0022contributors\u0022\u003E\u003Col class=\u0022contributor-list\u0022 id=\u0022contrib-group-1\u0022\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-1\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0002-8322-475X\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0002-8322-475X\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003EPaolo Antonio Ascierto\u003C\/span\u003E\u003Ca id=\u0022xref-aff-1-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-1\u0022\u003E1\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-2\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EBernard A Fox\u003C\/span\u003E\u003Ca id=\u0022xref-aff-2-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-2\u0022\u003E2\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-3\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EWalter J Urba\u003C\/span\u003E\u003Ca id=\u0022xref-aff-2-2\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-2\u0022\u003E2\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-4\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0002-0877-2932\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0002-0877-2932\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003EAna Carrizosa Anderson\u003C\/span\u003E\u003Ca id=\u0022xref-aff-3-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-3\u0022\u003E3\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-5\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0003-3901-9924\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0003-3901-9924\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003EMichael B Atkins\u003C\/span\u003E\u003Ca id=\u0022xref-aff-4-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-4\u0022\u003E4\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-6\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EErnest C Borden\u003C\/span\u003E\u003Ca id=\u0022xref-aff-5-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-5\u0022\u003E5\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-7\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EJulie R Brahmer\u003C\/span\u003E\u003Ca id=\u0022xref-aff-6-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-6\u0022\u003E6\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-8\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0002-3439-9844\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0002-3439-9844\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003ELisa H Butterfield\u003C\/span\u003E\u003Ca id=\u0022xref-aff-7-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-7\u0022\u003E7\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-9\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EAlessandra Cesano\u003C\/span\u003E\u003Ca id=\u0022xref-aff-8-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-8\u0022\u003E8\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-10\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0001-5085-3579\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0001-5085-3579\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003EDaniel S Chen\u003C\/span\u003E\u003Ca id=\u0022xref-aff-9-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-9\u0022\u003E9\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-11\u0022\u003E\u003Cspan class=\u0022name\u0022\u003ETanja D de Gruijl\u003C\/span\u003E\u003Ca id=\u0022xref-aff-10-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-10\u0022\u003E10\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-12\u0022\u003E\u003Cspan class=\u0022name\u0022\u003ERobert O Dillman\u003C\/span\u003E\u003Ca id=\u0022xref-aff-11-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-11\u0022\u003E11\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-13\u0022\u003E\u003Cspan class=\u0022name\u0022\u003ECharles G Drake\u003C\/span\u003E\u003Ca id=\u0022xref-aff-12-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-12\u0022\u003E12\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-14\u0022\u003E\u003Cspan class=\u0022name\u0022\u003ELeisha A Emens\u003C\/span\u003E\u003Ca id=\u0022xref-aff-13-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-13\u0022\u003E13\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-15\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EThomas F Gajewski\u003C\/span\u003E\u003Ca id=\u0022xref-aff-14-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-14\u0022\u003E14\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-16\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0002-6569-2912\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0002-6569-2912\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003EJames L Gulley\u003C\/span\u003E\u003Ca id=\u0022xref-aff-15-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-15\u0022\u003E15\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-17\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EF Stephen Hodi Jr\u003C\/span\u003E\u003Ca id=\u0022xref-aff-16-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-16\u0022\u003E16\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-18\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EPatrick Hwu\u003C\/span\u003E\u003Ca id=\u0022xref-aff-17-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-17\u0022\u003E17\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-19\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EDavid Kaufman\u003C\/span\u003E\u003Ca id=\u0022xref-aff-18-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-18\u0022\u003E18\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-20\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EHoward L Kaufman\u003C\/span\u003E\u003Ca id=\u0022xref-aff-19-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-19\u0022\u003E19\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-21\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EMichael T Lotze\u003C\/span\u003E\u003Ca id=\u0022xref-aff-20-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-20\u0022\u003E20\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-22\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EDouglas G McNeel\u003C\/span\u003E\u003Ca id=\u0022xref-aff-21-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-21\u0022\u003E21\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-23\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EKim A Margolin\u003C\/span\u003E\u003Ca id=\u0022xref-aff-22-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-22\u0022\u003E22\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-24\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EFrancesco M Marincola\u003C\/span\u003E\u003Ca id=\u0022xref-aff-23-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-23\u0022\u003E23\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-25\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EMichael J Mastrangelo\u003C\/span\u003E\u003Ca id=\u0022xref-aff-24-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-24\u0022\u003E24\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-26\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EMarcela V Maus\u003C\/span\u003E\u003Ca id=\u0022xref-aff-25-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-25\u0022\u003E25\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-27\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EDavid R Parkinson\u003C\/span\u003E\u003Ca id=\u0022xref-aff-26-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-26\u0022\u003E26\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-28\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EPedro J Romero\u003C\/span\u003E\u003Ca id=\u0022xref-aff-27-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-27\u0022\u003E27\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-29\u0022\u003E\u003Ca href=\u0022http:\/\/orcid.org\/0000-0002-0981-8875\u0022 class=\u0022bmjj-markup-orcid-logo\u0022 target=\u0022_blank\u0022\u003Ehttp:\/\/orcid.org\/0000-0002-0981-8875\u003C\/a\u003E\u003Cspan class=\u0022name\u0022\u003EPaul M Sondel\u003C\/span\u003E\u003Ca id=\u0022xref-aff-28-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-28\u0022\u003E28\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-30\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EStefani Spranger\u003C\/span\u003E\u003Ca id=\u0022xref-aff-29-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-29\u0022\u003E29\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-31\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EMario Sznol\u003C\/span\u003E\u003Ca id=\u0022xref-aff-30-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-30\u0022\u003E30\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-32\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EGeorge J Weiner\u003C\/span\u003E\u003Ca id=\u0022xref-aff-31-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-31\u0022\u003E31\u003C\/a\u003E, \u003C\/li\u003E\u003Cli class=\u0022contributor\u0022 id=\u0022contrib-33\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EJon M Wigginton\u003C\/span\u003E\u003Ca id=\u0022xref-aff-32-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-32\u0022\u003E32\u003C\/a\u003E and \u003C\/li\u003E\u003Cli class=\u0022last\u0022 id=\u0022contrib-34\u0022\u003E\u003Cspan class=\u0022name\u0022\u003EJeffrey S Weber\u003C\/span\u003E\u003Ca id=\u0022xref-aff-33-1\u0022 class=\u0022xref-aff\u0022 href=\u0022#aff-33\u0022\u003E33\u003C\/a\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Col class=\u0022affiliation-list\u0022\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-1\u0022 name=\u0022aff-1\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E1\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EIstituto Nazionale Tumori IRCCS Fondazione \u0027G. Pascale\u0027\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENaples\u003C\/span\u003E, Italy\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-2\u0022 name=\u0022aff-2\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E2\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EEarle A. Chiles Research Institute\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EProvidence Cancer Institute\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EPortland\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EOregon\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-3\u0022 name=\u0022aff-3\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E3\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EHarvard Medical School\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EBoston\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMassachusetts\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-4\u0022 name=\u0022aff-4\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E4\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EGeorgetown Lombardi Comprehensive Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EWashington\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EDC\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-5\u0022 name=\u0022aff-5\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E5\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EUniversity of Wisconsin Clinical Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMadison\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EWisconsin\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-6\u0022 name=\u0022aff-6\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E6\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EJohns Hopkins University School of Medicine\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003ESidney Kimmel Comprehensive Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EBaltimore\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMaryland\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-7\u0022 name=\u0022aff-7\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E7\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EResearch\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EParker Institute for Cancer Immunotherapy\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ESan Francisco\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ECalifornia\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-8\u0022 name=\u0022aff-8\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E8\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EESSA Pharma Inc\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ERedwood City\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ECalifornia\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-9\u0022 name=\u0022aff-9\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E9\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EIGM Biosciences Inc\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMountain View\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ECalifornia\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-10\u0022 name=\u0022aff-10\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E10\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EMedical Oncology - Amsterdam University Medical Centers\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EVrije Universiteit-Cancer Center Amsterdam\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EAmsterdam\u003C\/span\u003E, The Netherlands\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-11\u0022 name=\u0022aff-11\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E11\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EAIVITA Biomedical, Inc\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EIrvine\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ECalifornia\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-12\u0022 name=\u0022aff-12\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E12\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EHerbert Irving Comprehensive Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EColumbia University Medical Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENew York\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENew York\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-13\u0022 name=\u0022aff-13\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E13\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EUPMC Hillman Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EPittsburgh\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EPennsylvania\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-14\u0022 name=\u0022aff-14\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E14\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EPathology and Medicine, Immunology and Cancer Program\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EUniversity of Chicago\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EChicago\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EIllinois\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-15\u0022 name=\u0022aff-15\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E15\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003ENational Cancer Institute\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EBethesda\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMaryland\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-16\u0022 name=\u0022aff-16\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E16\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EDana Farber Cancer Institute\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EBoston\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMassachusetts\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-17\u0022 name=\u0022aff-17\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E17\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EUniversity of Texas MD Anderson Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EHouston\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ETexas\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-18\u0022 name=\u0022aff-18\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E18\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EBill \u0026amp; Melinda Gates Medical Research Institute\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ECambridge\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMassachusetts\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-19\u0022 name=\u0022aff-19\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E19\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EImmuneering Corp New York\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENew York\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENew York\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-20\u0022 name=\u0022aff-20\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E20\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EUniversity of Pittsburgh School of Medicine\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EPittsburgh\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EPennsylvania\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-21\u0022 name=\u0022aff-21\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E21\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003ECarbone Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EUniversity of Wisconsin-Madison\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMadison\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EWisconsin\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-22\u0022 name=\u0022aff-22\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E22\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EMedical Oncology\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003ECity of Hope National Medical Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EDuarte\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ECalifornia\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-23\u0022 name=\u0022aff-23\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E23\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003ERefuge Biotechnologies\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMenlo Park\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ECalifornia\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-24\u0022 name=\u0022aff-24\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E24\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EThomas Jefferson Medical College\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EPhiladelphia\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EPennsylvania\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-25\u0022 name=\u0022aff-25\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E25\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EMassachusetts General Hospital Cancer Center, Harvard Medical School\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EMassachusetts General Hospital\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EBoston\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMassachusetts\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-26\u0022 name=\u0022aff-26\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E26\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EESSA Pharma Inc\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EPalo Alto\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ECalifornia\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-27\u0022 name=\u0022aff-27\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E27\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EOncology\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EUniversity of Lausanne\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ELausanne\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EVD\u003C\/span\u003E, Switzerland\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-28\u0022 name=\u0022aff-28\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E28\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EPediatrics\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EUniversity of Wisconsin Madison\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMadison\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EWisconsin\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-29\u0022 name=\u0022aff-29\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E29\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EMassachusetts Institute of Technology Koch Institute for Integrative Cancer Research\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ECambridge\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMassachusetts\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-30\u0022 name=\u0022aff-30\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E30\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EYale Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EYale School of Medicine\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENew Haven\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EConnecticut\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-31\u0022 name=\u0022aff-31\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E31\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EHolden Comprehensive Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003EThe University of Iowa\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EIowa City\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EIowa\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-32\u0022 name=\u0022aff-32\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E32\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003EMacroGenics Inc\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ERockville\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003EMaryland\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003Cli class=\u0022aff\u0022\u003E\u003Ca id=\u0022aff-33\u0022 name=\u0022aff-33\u0022\u003E\u003C\/a\u003E\u003Caddress\u003E\n\u003Csup\u003E33\u003C\/sup\u003E\u003Cspan class=\u0022institution\u0022\u003ELaura and Isaac Perlmutter Comprehensive Cancer Center\u003C\/span\u003E, \u003Cspan class=\u0022institution\u0022\u003ENYU Langone Medical Center\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENew York\u003C\/span\u003E, \u003Cspan class=\u0022addr-line\u0022\u003ENew York\u003C\/span\u003E, USA\n\u003C\/address\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Col class=\u0022corresp-list\u0022\u003E\u003Cli class=\u0022corresp\u0022 id=\u0022corresp-1\u0022\u003E\u003Cspan class=\u0022corresp-label\u0022\u003ECorrespondence to\u003C\/span\u003E\n Dr Jeffrey S Weber; \u003Cspan class=\u0022em-link\u0022\u003E\u003Cspan class=\u0022em-addr\u0022\u003EJeffrey.Weber{at}nyulangone.org\u003C\/span\u003E\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup abstract-with-bc\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-custom pane-1\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cp\u003E\u003Ca href=\u0022https:\/\/doi.org\/10.1136\/jitc-2020-000878\u0022 target=\u0022_new\u0022\u003Ehttps:\/\/doi.org\/10.1136\/jitc-2020-000878\u003C\/a\u003E\u003C\/p\u003E\n  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-altmetrics\u0022\u003E\n  \n        \u003Ch2 class=\u0022pane-title\u0022\u003EStatistics from Altmetric.com\u003C\/h2\u003E\n    \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv data-badge-details=\u0022right\u0022 data-badge-type=\u0022medium-donut\u0022 data-doi=\u002210.1136\/jitc-2020-000878\u0022 data-hide-no-mentions=\u0022true\u0022 class=\u0022altmetric-embed\u0022\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-custom pane-2 permissions-box\u0022\u003E\n  \n        \u003Ch2 class=\u0022pane-title\u0022\u003ERequest Permissions\u003C\/h2\u003E\n    \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cp\u003EIf you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center\u0026rsquo;s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.\u003C\/p\u003E\n  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-panels-ajax-pane-content permissions-box pane-highwire-permission-link\u0022 id=\u0022request-permissions\u0022\u003E\n  \n        \u003Ch2 class=\u0022pane-title\u0022\u003E\u003Cspan class=\u0022panels-ajax-pane-title\u0022 data-pid=\u0022new-70fd4c70-563e-4b94-ae3b-2a97f3980c13\u0022\u003E\u003C\/span\u003E\u003C\/h2\u003E\n    \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022panels-ajax-pane panels-ajax-pane-new-70fd4c70-563e-4b94-ae3b-2a97f3980c13\u0022 data-pid=\u0022new-70fd4c70-563e-4b94-ae3b-2a97f3980c13\u0022\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 class=\u0022content-block-markup\u0022 xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003E\u003Ca href=\u0022\/keyword\/immunomodulation\u0022 class=\u0022hw-term hw-article-keyword hw-article-keyword-immunomodulation\u0022 rel=\u0022nofollow\u0022\u003Eimmunomodulation\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003E\u003Ca href=\u0022\/keyword\/inflammation-mediators\u0022 class=\u0022hw-term hw-article-keyword hw-article-keyword-inflammation-mediators\u0022 rel=\u0022nofollow\u0022\u003Einflammation mediators\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003EThe\nhypoxia and profound inflammatory response associated with the pneumonitis\nobserved with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan, China, Northern Italy and in the USA, the Seattle and New York City areas. The Society for Immunotherapy of Cancer (SITC) stands along with and supports our colleagues in emergency departments, intensive care units (ICUs) and inpatient wards in the global effort to overcome this unprecedented pandemic. It is becoming apparent that the \u0026acirc;\u0026#128;\u0026#152;ground glass\u0026acirc;\u0026#128;\u0026#153; infiltrative appearance seen on CT scans from patients with COVID-19 with pneumonitis is reminiscent of imaging from patients with immune checkpoint inhibitor (ICI)-induced pneumonitis.\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1 2\u003C\/a\u003E Additionally, elevated interleukin-6 (IL-6) is a hallmark inflammatory signature seen in serum of patients with severe COVID-19 acute respiratory distress.\u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E Many of us have experience with the administration of immune-modulatory agents, which is why the cancer immunotherapy community is poised to contribute to the current fight against COVID-19.\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EOne possibility is to encourage the use of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (Actemra\u003Csup\u003ETM\u003C\/sup\u003E, Roche-Genentech), sarilumab (Kevzara\u003Csup\u003ETM\u003C\/sup\u003E, Regeneron) and siltuximab (Sylvant\u003Csup\u003ETM\u003C\/sup\u003E, EUSA Pharma) that are Food and Drug Administration (FDA) approved for various conditions, including rheumatological disease and the lymphoproliferative disorder Castleman\u0026acirc;\u0026#128;\u0026#153;s syndrome. These agents could be used on easily and immediately available compassionate use protocols that could be approved on an emergency basis by all institutional review boards (IRBs) around the world for critically ill patients with COVID-19-induced hypoxia. Tocilizumab also is already FDA approved to manage cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor T cell therapy.\u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4 5\u003C\/a\u003E In addition, tocilizumab has been shown to reduce toxicity in patients treated with ICIs who were steroid refractory,\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E and has been added to the ICI agents ipilimumab and nivolumab in an ongoing US phase II study (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT03999749\u0026amp;atom=%2Fjitc%2F8%2F1%2Fe000878.atom\u0022\u003ENCT03999749\u003C\/a\u003E) to ameliorate immune-related toxicity. In Castleman\u0026acirc;\u0026#128;\u0026#153;s disease, a lymphoproliferative disorder caused by Kaposi\u0026acirc;\u0026#128;\u0026#153;s Sarcoma Herpesvirus, a pathogen that produces viral IL-6, tocilizumab has been shown to reduce viral loads.\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E Tocilizumab is also being explored as a potential supportive care measure for the management of CRS in patients with cancer treated with a number of CD3-based bispecific molecules. Now, data from the frontlines of the pandemic indicates that the agent may offer lifesaving benefit for COVID-19 patients with respiratory distress.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EEmerging evidence suggests that high levels of C reactive protein (CRP) and IL-6 are observed in patients infected with COVID-19.\u003Ca id=\u0022xref-ref-1-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1 8\u003C\/a\u003E Anecdotal experience on the use of tocilizumab at doses comparable to those used for the management of CRS from investigators in Italy\u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E and from China\u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E has reported rapid improvement in both intubated and non-intubated patients. In these reports, expeditious administration of anti-IL-6R therapy for patients in acute respiratory distress has been critical. A recent study protocol to evaluate the efficacy of tocilizumab in COVID-19-induced pneumonitis accrued over 300 patients worldwide in less than 24\u0026acirc;\u0026#128;\u0026#137;hours. Additionally, Genentech will also provide 10\u0026acirc;\u0026#128;\u0026#137;000 vials of tocilizumab to the US Strategic National Stockpile.\u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E Tocilizumab was also approved in China in March 2020, for the treatment of patients with COVID-19 with serious lung damage and elevated IL-6. Sponsors, investigators and regulators have moved with unprecedented speed and collaboration to initiate protocols to formally study the safety and efficacy of antiviral agents and vaccines, as well as various anti-IL-6 antibodies in patients with COVID-19. In the USA, a trial of sarilumab in the COVID-19 setting is ongoing.\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E\n\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EAlthough randomized data definitively showing that IL-6R blockade benefits patients with COVID-19-induced pneumonitis are currently lacking, we propose that an effort should be made to maximize the availability of anti-IL-6 agents, includingtocilizumab and sarilumab for use on a compassionate basis to critically illhospitalized SARS-CoV-2-infected patients during this extraordinary situation. In addition, consideration should be given to focus efforts on rapidly expanding the ability of clinicians and clinical investigators to access investigational anti-IL-6 agents, in particular for those agents where phase 1 and\/or phase 2 studies have been completed, and acceptable safety has been demonstrated. Even if the primary impact of a single dose of these drugs is to accelerate recovery and get patients off ventilator support and out of the ICU more rapidly, this could significantly decompress our severely overburdened healthcare systems. We suggest that straightforward parameters including complete blood counts and differentials, serum lactate dehydrogenase (LDH), ferritin, CRP and IL-6 be recorded in treated patients, that serum be retained for future analyses, and simple clinical parameters be assessed including time in ICU, days of hospitalization and pulmonary parameters, including forced expiratory volume in 1 s (for non-intubated patients), fractional inspired oxygen (FiO\u003Csub\u003E2\u003C\/sub\u003E), arterial oxygen tension\/FiO\u003Csub\u003E2\u003C\/sub\u003E ratio and type of oxygen supplementation need be recorded pre-anti-IL-6R and post-anti-IL-6R therapy. A simple compassionate use protocol could be assembled from existing templates, and all efforts should be made for emergency approval of the use of IL-6R blocking antibodies by local IRBs within 24\u0026acirc;\u0026#128;\u0026#137;hours of the request being made. Additionally, consideration should be given by pharma and biotech to redirect the use of facilities and increase personnel involved in drug manufacturing and those serving as liaisons to the frontlines to facilitate drug availability. Extraordinary times call for extraordinary measures, and SITC calls on all involved, including pharmaceutical sponsors, health authorities and IRBs, to continue to move swiftly and creatively to remove barriers and increase access to agents like anti-IL-6R drugs that may improve our care for COVID-19 pneumonitis.\u003C\/p\u003E\u003Cdiv class=\u0022section ack\u0022 id=\u0022ack-1\u0022\u003E\u003Ch2\u003EAcknowledgments\u003C\/h2\u003E\u003Cp id=\u0022p-6\u0022\u003EThe authors thank the clinicians working tirelessly on the frontlines of the COVID-19 pandemic. The authors also acknowledge SITC staff for their contributions including Sam Million Weaver, PhD for medical writing and editorial support and Angela Kilbert for project management and assistance. Additionally, the authors wish to thank the society for supporting the manuscript development.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list\u0022\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 1 in text\u0022 id=\u0022ref-1\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-8.1.e000878.1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\n\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EYe\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\n\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EChest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEur Radiol\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E. doi:\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1007\/s00330-020-06801-0\u0022\u003Edoi:10.1007\/s00330-020-06801-0\u003C\/a\u003E. [Epub ahead of print: 19 Mar\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-pmid-sep\u0022\u003E 2020].\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32193638\u003C\/span\u003E\n\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 2 in text\u0022 id=\u0022ref-2\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-8.1.e000878.2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\n\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EPuzanov\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EDiab\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EAbdallah\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\n\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EManaging toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Immunother Cancer\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E5\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/s40425-017-0300-z\u0022\u003Edoi:10.1186\/s40425-017-0300-z\u003C\/a\u003E\n\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference 3 in text\u0022 id=\u0022ref-3\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-8.1.e000878.3\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\n\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EYang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ\u003C\/span\u003E\n\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EClinical features of 69 cases with coronavirus disease 2019 in Wuhan, China\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClin Infect Dis\u003C\/abbr\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1093\/cid\/ciaa272\u0022\u003Edoi:10.1093\/cid\/ciaa272\u003C\/a\u003E\n\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 4 in text\u0022 id=\u0022ref-4\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-8.1.e000878.4\u0022 data-doi=\u002210.1158\/2159-8290.CD-16-0040\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\n\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003ETeachey\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDT\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003ELacey\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESF\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EShaw\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\n\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EIdentification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer Discov\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E664\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E79\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1158\/2159-8290.CD-16-0040\u0022\u003Edoi:10.1158\/2159-8290.CD-16-0040\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-pmid-sep\u0022\u003E\n\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27076371\u003C\/span\u003E\n\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BDiscov%26rft.volume%253D6%26rft.spage%253D664%26rft_id%253Dinfo%253Adoi%252F10.1158%252F2159-8290.CD-16-0040%26rft_id%253Dinfo%253Apmid%252F27076371%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1158\/2159-8290.CD-16-0040\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=27076371\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F8%2F1%2Fe000878.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 5 in text\u0022 id=\u0022ref-5\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-8.1.e000878.5\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\n\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EMaude\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESL\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarrett\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003ETeachey\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDT\u003C\/span\u003E\n\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EManaging cytokine release syndrome associated with novel T cell-engaging therapies\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECancer J\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E119\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E22\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1097\/PPO.0000000000000035\u0022\u003Edoi:10.1097\/PPO.0000000000000035\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-pmid-sep\u0022\u003E\n\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24667956\u003C\/span\u003E\n\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DCancer%2BJ%26rft.volume%253D20%26rft.spage%253D119%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F8%2F1%2Fe000878.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6 in text\u0022 id=\u0022ref-6\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-8.1.e000878.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\n\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EStroud\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECR\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EHegde\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003ECherry\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\n\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ETocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Oncol Pharm Pract\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E25\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E551\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E7\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1177\/1078155217745144\u0022\u003Edoi:10.1177\/1078155217745144\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-pmid-sep\u0022\u003E\n\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29207939\u003C\/span\u003E\n\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DJ%2BOncol%2BPharm%2BPract%26rft.volume%253D25%26rft.spage%253D551%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F8%2F1%2Fe000878.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7 in text\u0022 id=\u0022ref-7\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-8.1.e000878.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\n\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003ERamaswami\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003ELurain\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EWidell\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\n\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPilot Study of Tocilizumab in Patients with HIV and Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBlood\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E132\u003C\/span\u003E:\u003Cspan class=\u0022cit-elocation-id\u0022\u003E2894\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1182\/blood-2018-99-113119\u0022\u003Edoi:10.1182\/blood-2018-99-113119\u003C\/a\u003E\n\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-2\u0022 title=\u0022View reference 8 in text\u0022 id=\u0022ref-8\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-8.1.e000878.8\u0022 data-doi=\u002210.1016\/S0140-6736(20)30628-0\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\n\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EMehta\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EMcAuley\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDF\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\n\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ECOVID-19: consider cytokine storm syndromes and immunosuppression\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E395\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1033\u003C\/span\u003E\u0026acirc;\u0026#128;\u0026#147;\u003Cspan class=\u0022cit-lpage\u0022\u003E4\u003C\/span\u003E.\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1016\/S0140-6736(20)30628-0\u0022\u003Edoi:10.1016\/S0140-6736(20)30628-0\u003C\/a\u003E\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-pmid-sep\u0022\u003E\n\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-pmid\u0022\u003E\u003Cspan class=\u0022cit-pub-id-scheme-pmid\u0022\u003Epmid:\u003C\/span\u003Ehttp:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32192578\u003C\/span\u003E\n\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022%7Bopenurl%7D?query=rft.jtitle%253DLancet%26rft.volume%253D395%26rft.spage%253D1033%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0140-6736%252820%252930628-0%26rft_id%253Dinfo%253Apmid%252F32192578%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S0140-6736(20)30628-0\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=32192578\u0026amp;link_type=MED\u0026amp;atom=%2Fjitc%2F8%2F1%2Fe000878.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference 9 in text\u0022 id=\u0022ref-9\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-8.1.e000878.9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\n\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EAscierto\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPA\u003C\/span\u003E\n\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPersonal communication\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-10-1\u0022 title=\u0022View reference 10 in text\u0022 id=\u0022ref-10\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-8.1.e000878.10\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\n\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EXiaoling\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003EMingfeng\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\n\u003C\/span\u003E, \u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\n\u003Cspan class=\u0022cit-name-surname\u0022\u003ETiantian\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\n\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E\n\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EEffective treatment of severe COVID-19 patients with tocilizumab\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference 11 in text\u0022 id=\u0022ref-11\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-8.1.e000878.11\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EGenentech\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EGenentech Announces FDA approval of clinical trial for Actemra to treat hospitalized patients with severe COVID-19 pneumonia\u003C\/span\u003E. Available: \u003Ca href=\u0022https:\/\/www.gene.com\/media\/press-releases\/14843\/2020-03-23\/genentech-announces-fda-approval-of-clin\u0022\u003Ehttps:\/\/www.gene.com\/media\/press-releases\/14843\/2020-03-23\/genentech-announces-fda-approval-of-clin\u003C\/a\u003E\n\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 12 in text\u0022 id=\u0022ref-12\u0022\u003E\u0026acirc;\u0026#134;\u0026micro;\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-8.1.e000878.12\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Col class=\u0022cit-auth-list\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ESANOFI\u003C\/span\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003Ccite\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ESanofi and Regeneron begin global Kevzara\u0026Acirc;\u0026reg; (sarilumab) clinical trial program in patients with severe COVID-19\u003C\/span\u003E. Available: \u003Ca href=\u0022http:\/\/www.news.sanofi.us\/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19\u0022\u003Ehttp:\/\/www.news.sanofi.us\/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19\u003C\/a\u003E\n\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup footnotes\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 class=\u0022content-block-markup\u0022 xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 class=\u0022section fn-group\u0022 id=\u0022fn-group-1\u0022\u003E\u003Ch2\u003EFootnotes\u003C\/h2\u003E\u003Cul\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-1\u0022\u003E\u003Cp id=\u0022p-7\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003ETwitter\u003C\/span\u003E @EmensLeisha, @gulleyj1, @kmargolin, @JITCancer\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-2\u0022\u003E\u003Cp id=\u0022p-8\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003ECorrection notice\u003C\/span\u003E Since the online publication of this article, the authors have noticed errors in author names, affiliations, the competing interests section and also the main text.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-3\u0022\u003E\u003Cp id=\u0022p-9\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003EFunding\u003C\/span\u003E The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-conflict\u0022 id=\u0022fn-4\u0022\u003E\u003Cp id=\u0022p-10\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003ECompeting interests\u003C\/span\u003E PAA: Consultant\/Advisory Role: Bristol-Myers Squibb, Roche-Genentech, Merck Sharp \u0026amp; Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar; Research Funds: Bristol-Myers Squibb, Roche-Genentech, Array; Travel support: MSD; BAF: Cofounder\/Stock: UbiVac; Consulting\/Research Support: Macrogenics, OncoSec, Shimadzu, Viralytics (Merck); Consulting (II-ON)\/Research Support: Bristol-Myers Squibb; Consulting\/Stock: PrimeVax; Research Support: NanoString, Quanterix; SAB: Argos, Bayer, CellDex, UltiVue; SAB\/Institutional Research Support: AstraZeneca (MedImmunne); SAB\/Research Support: Akoya BioScience (Perkin Elmer), Definiens; WJU: Advisory Board: MedImmune, Bristol-MyerS Squibb; Research Support\/Contracted Work: Bristol-Myers Squibb; Research Support: MedImmune; ACA: Consulting Fees: Tizona Therapeutics, Compass Therapeutics, Zumutor Biologics; Ownership Interest: VBI vaccines; Scientific Advisory Board: Compass Therapeutics, Zumutor Biologics Inc, Tizona Therapeutics; MBA: Advisory Board: Bristol-Myers Squibb, Merck, Novartis, Arrowhead, Pfizer, Galactone, Werewolf, Fathom; Consultant: Bristol-Myers Squibb, Novartis, Genetch-Roche, Exelixis, Eisai, Aveo, Array, AstraZeneca, Idera, Aduro, ImmunoCore, Boehringer-Ingelheim, Lion, Newlink, Surface, Alexion, Acceleron, Lynx, Cote; Research Support: Bristol-Myers Squibb; Stock Options: Werewolf; JRB: Advisory Board: Amgen, BMS Celgene, Eli Lilly; Genentech, Merck, Syndax; Consulting: BMS, Genentech, Eli Lilly, Merck; Research\/Grant Funding: MedImmune\/AstraZeneca, Merck; LHB: Consulting Fees: StemImmune\/Calidi Scientific and Medical Advisory Board, NextCure; Scientific Advisory Board: Replimmune, Western Oncolytics, Torque Therapeutics, Khloris, Pyxis, Cytomix, Roche-Genentech Biomarkers Roundtable; AC: Consulting Fees: Refuge Bio, Arch Oncology, Qognit, Nanostring; Salary: ESSA Pharma; DSC: Ownership Interest: IGM Biosciences; Salary: IGM Biosciences; CGD: Consultant Fees: Agenus, AstraZeneca, Dendreon, Eli Lilly, Janssen, Merck, Pierre Fabre, Roche\/Genetech; Ownership Interests: Compugen, Harpoon, Kleo; Patents\/Royalties: AstraZeneca, Bristol-Myers Squibb, Janssen; Research Funding: Aduro Biotech, Bristol-Myers Squibb, Janssen; LAE: Contracted Research: Aduro Biotech, AstraZeneca, Bristol-Myers Squibb, Corvus, EMD Serono, Genentech, F Hoffman La Roche, Maxcyte, Merck, Tempest; Consulting Fees: Genentech, F Hoffman La Roche, Syndax, Eli Lilly, AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Genentech, F Hoffman La Roche, Gritstone, Medimmune, Macrogenics, Novartis, Peregrine, Replimune, Silverback, Vaccinex; IP Rights: Aduro Biotech; Royalty: Elsevier; Salary: University of Pittsburgh, UPMC UPP; Grants from non-industry entities: HeritX Incorporated, NSABP Foundation, Translational Breast Cancer Research Consortium, Breast Cancer Research Foundation, National Cancer Institute, Department of Defense, Johns Hopkins University, University of California San Francisco; TDG: Consulting Fees: DCPrime BV, Macrophage Pharma, Partner Therapeutics; Contracted Research: Idera Pharmaceuticals, Macrophage Parma; IP Rights\/Patents: The use of cytostatics for the accelerated differentiation of DC WO2009019320-A2; WO2009019320-A3; AU2008285598-A1; EP2281030-A2; CA2724018-A1; US2011117051-A1. US8,470, 789B2 of DC prime BV, Immunoglobulins binding human V\u0026Atilde;\u0026#142;\u0026Acirc;\u0026sup3;9V\u0026Atilde;\u0026#142;\u00272 T cell receptors, CD1d domain antibodies targeting CD1d P32016NL00 EP16715360.0-1412, LAVA Tx BV; Ownership Interest: LAVA Therapeutics BV (stocks), Salary: Vrije Universiteit Medical Center Amsterdam; TFG: Consultant\/Advisory Board: Roche-Genentech, Merck, Abbvie, Bayer, Jounce, Aduro, Fog Pharma, Adaptimmune, FivePrime, Sanofi; Research Support: Roche-Genentech, Bristol-Myers Squibb, Merck, Incyte, Seattle Genetics, Celldex, Ono, Evelo, Bayer, Adure; IP\/Licensing: Aduro, Evelo; Cofounder\/shareholder: Jounce; FSH: Advisory Board: Aduro, Amgen, 7 Hills Pharma, Compass Therapeutics, Takeda, Rheos, Surface, Verastem; Advisory Board\/Equity: Poinyr; Consulting Fees: Genetech\/Roche, Bayer, Bristol-Myers Squibb, EMD Serono, Kairos, Merck, Partners Therapeutics, Sanofi, Pfizer, Pieris Pharmaceutical; Scientific Advisory Board\/Equity: Apricity, Torque, Bicara; Grant\/Royalties to Institution: Bristol-Myers Squibb, Novartis; PH: Consulting Fees: Immatics, Sanofi, Dragonfly, GlaxoSmithKline; DK: Scientific Advisory Board, Celsius Therapeutics, Hookipa Pharma; HLK: Salary: Immuneering Corporation; MTL: Consulting Fees: Torque, Repertone, Checkmate, Salary: Iovance; FMM: Consulting Fees: Calidi Biotechnologies, Salary: Refuge Biotechnologies; KAM: Consulting Fees: ImaginAb SAB, Iovance DMC, Neoleukin ad board (Non CME Services, \u0026lt;10k\/year from each entity); MVM: Consulting\/Advising: Adaptimmune Therapeutics, Agentus, Agenus inc, Allogene, Arcellx, Bluebird Bio, GSK, Incysus, Kite Pharma, Novartis; Scientific Advisory Boards: Century Therapeutics, CRISPR Therapeutics. TCR2, WindMIL Therapeutics; DGM: Clinical Trial Contracts (Served as PI): Merck, Bristol-Myers Squibb, Janssen, Pfizer, Novartis; Consulting Fees: Madison Vaccines; Contracted Research: Madison Vaccines, Merck; Ownership Interest: Madison Vaccines; DRP: President \u0026amp; CEO: ESSA Pharma; Board of Directors: CTI BioPharma, Tocagen, 3SBio; Scientific Advisory Board: Caris Life Science; PJR: Scientific advisory board: Immatics Biotechnologies, NexImmune, Life Science Partners, Speaker Fees: Bristol-Myers Squibb, Roche Pars, Astra Zeneca; SS: Consulting Fees: Arcus, Dragonfly, Merck, Ribon, Replimune, Takeda, Tango; Partner Salary: Nanoview Biosciences; Salary: MIT; MS: Consulting fees: Abbvie, Allakos, Anaeropharma, Almac, Array, AstraZeneca, Biodesix, Bristol-Myers Squibb, Chugai-Roche, Genentech-Roche, Genmab, Genocea, GI Innovation, Hinge, Immunocore, Innate pharma, Lilly, Modulate Therapeutics, Molecular Partner, Nektar, Newlink Genetics, Novartis, Seattle Genetics, Zelluna; Scientific Advisory Boards: Adaptimmune, Lycera (no longer active), Nanobot, Omniox, Pieris, Symphogen, Torque; Ownership Interest (Stock Options): Nanobot, Torque; GJW: Consulting Fees: Cancer Centers at the Universities of Colorado, Hawaii, Kansas, Kentucky, Ohio State, Virginia, Wake Forest, Oregon Health Sciences, University of Illinois Chicago, Memorial Sloan Kettering; Contracted Research: Checkmate Pharmaceuticals; JMW: Consulting Fees: Western Oncolytics; Employee and Shareholder: MacroGenics; JSW: Consulting: Merck, Genentech, Astra Zeneca, GSK, Novartis, Nektar, Medivation, Celldex, Incyte and EMD Serono; Advisory Board: BMS, Celldex, CytoMx, Incyte, Biond, Protean, CV6 and Sellas; Equity: CytoMx, Biond and Altor; Patent\/IP: Moffitt Cancer Center IPILIMUMAB biomarker, BioDesix PD-1 biomarker\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-5\u0022\u003E\u003Cp id=\u0022p-11\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003EPatient consent for publication\u003C\/span\u003E Not required.\u003C\/p\u003E\u003C\/li\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-6\u0022\u003E\u003Cp id=\u0022p-12\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003EProvenance and peer review\u003C\/span\u003E Commissioned; externally peer reviewed.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003Cdiv class=\u0022panel-separator\u0022\u003E\u003C\/div\u003E\u003Cdiv class=\u0022panel-pane pane-dfp-pane\u0022\u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv id=\u0022dfp-ad-mpu-wrapper\u0022 class=\u0022dfp-tag-wrapper\u0022\u003E\n\n\u003Cdiv id=\u0022dfp-ad-mpu\u0022 class=\u0022dfp-tag-wrapper\u0022\u003E\n  \u003Cscript type=\u0022text\/javascript\u0022\u003E\n    googletag.cmd.push(function() {\n      googletag.display(\u0022dfp-ad-mpu\u0022);\n    });\n  \u003C\/script\u003E\u003C\/div\u003E\n\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/www.highwirestage.com\/sites\/default\/files\/js\/js_am8GAfrhW3uXc7HVCmqF3MltMmNunvhyJ6MM_6EffRE.js\u0022\u003E\u003C\/script\u003E\u003C\/body\u003E\u003C\/html\u003E\n"}